http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6852698-B2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 |
| filingDate | 2001-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb3a6b9aba73482bb9be3033919ff53c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bf6444a054ef121116f1e0ce5ec96db |
| publicationDate | 2005-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6852698-B2 |
| titleOfInvention | Free radical scavengers or promoters thereof as therapeutic adjuvants in preterm parturition |
| abstract | The usage of compounds that improve fetal and neonatal outcome of preterm birth is described. These compounds are scavengers of ROS, their precursors, and agents that induce production of the scavengers. Examples of these compounds are glutathione, NAC, antioxidants, and spin trapping compounds. These compounds improve fetal outcome by inhibiting a fetal inflammatory process that may affect the fetus independently of prematurity. This fetal inflammatory response is characterized by increased cytokine and matrix metalloproteases (MMP) levels both in the mother and fetus and may be modulated by ROS at different levels. Targeting ROS formation with compounds such as specific antioxidants, glutathione or spin trapping compounds, their precursors, and/or agents which induce their production will suppress both the direct effects of ROS and its indirect effects through cytokines and MMPs already circulating in the system. This therapeutical intervention would limit the pathophysiologoical chain of events that ultimately leads to PPROM, preterm birth and/or adverse fetal and neonatal outcome. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109182260-A |
| priorityDate | 2000-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 226.